Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Hata T, Uemura M, Danno K, Yoshioka S, Matsuda C, Kagawa Y, Shingai T, Suzuki Y, Tei M, Tanida T, Komori T, Okamura S, Ota H, Takemoto H, Ogino T, Miyoshi N, Yamamoto H, Murata K, Doki Y, Eguchi H. Hata T, et al. Sci Rep. 2024 Nov 2;14(1):26434. doi: 10.1038/s41598-024-73222-0. Sci Rep. 2024. PMID: 39488510 Free PMC article. Clinical Trial.
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T, Tamagawa H, Matsuda C, Murata K, Fukunaga M, Ota H, Hasegawa J, Tsujie M, Fukuzaki T, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: hata t. Oncology. 2015;89(3):152-8. doi: 10.1159/000381718. Epub 2015 May 8. Oncology. 2015. PMID: 25967649 Clinical Trial.
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim HM, Kudo T, Murata K, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Mizushima T, et al. Among authors: hata t. Cancer Chemother Pharmacol. 2017 Jul;80(1):81-90. doi: 10.1007/s00280-017-3336-3. Epub 2017 May 16. Cancer Chemother Pharmacol. 2017. PMID: 28510802 Clinical Trial.
Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Danno K, Hata T, Tamai K, Fujie Y, Ide Y, Kim HM, Ohnishi T, Morita S, Yoshioka S, Kudo T, Nishimura J, Matsuda C, Akamatsu H, Mizushima T, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka; Colorectal Cancer Treatment Group (MCSGO). Danno K, et al. Among authors: hata t. Cancer Chemother Pharmacol. 2017 Oct;80(4):777-785. doi: 10.1007/s00280-017-3419-1. Epub 2017 Aug 19. Cancer Chemother Pharmacol. 2017. PMID: 28825216 Clinical Trial.
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer.
Nishimura J, Hasegawa J, Kato T, Yoshioka S, Noura S, Kagawa Y, Yasui M, Ikenaga M, Murata K, Hata T, Matsuda C, Mizushima T, Yamamoto H, Doki Y, Mori M; Clinical Study Group of Osaka University (CSGO) Colorectal Group. Nishimura J, et al. Among authors: hata t. Cancer Chemother Pharmacol. 2018 Oct;82(4):707-716. doi: 10.1007/s00280-018-3663-z. Epub 2018 Aug 4. Cancer Chemother Pharmacol. 2018. PMID: 30078098 Clinical Trial.
Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T, Ikeda M, Kato T, Ikeda A, Nishimura J, Hata T, Matsuda C, Satoh T, Mori M, Doki Y. Mizushima T, et al. Among authors: hata t. BMC Cancer. 2019 Sep 18;19(1):929. doi: 10.1186/s12885-019-6122-2. BMC Cancer. 2019. PMID: 31533662 Free PMC article. Clinical Trial.
Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study.
Hata T, Hagihara K, Tsutsui A, Akamatsu H, Ohue M, Shingai T, Tei M, Ikenaga M, Kim HM, Osawa H, Takemoto H, Konishi K, Uemura M, Matsuda C, Mizushima T, Murata K, Ohno Y, Doki Y, Eguchi H. Hata T, et al. Oncologist. 2021 May;26(5):e735-e741. doi: 10.1002/onco.13724. Epub 2021 Mar 2. Oncologist. 2021. PMID: 33604941 Free PMC article. Clinical Trial.
Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer.
Kato T, Kudo T, Kagawa Y, Murata K, Ota H, Noura S, Hasegawa J, Tamagawa H, Ohta K, Ikenaga M, Miyazaki S, Komori T, Uemura M, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T, Ohno Y, Yamamoto H, Doki Y, Eguchi H. Kato T, et al. Among authors: hata t. Sci Rep. 2023 Feb 9;13(1):2331. doi: 10.1038/s41598-022-24057-0. Sci Rep. 2023. PMID: 36759648 Free PMC article. Clinical Trial.
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hata T, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31. Cancer Chemother Pharmacol. 2013. PMID: 23543294 Clinical Trial.
2,149 results